Sep. 17, 2009 (Business Wire) -- ZOLL Medical Corporation (NasdaqGS: ZOLL), a manufacturer of resuscitation devices and related software solutions, announced today that Fortune magazine has ranked ZOLL #85 on its list of the 100 fastest growing companies.
In an article entitled “Defying the Downturn” in the August 31 issue, Fortune calls these companies “the world’s supercharged performers.” Even amid the worst economic slump since the Great Depression, some companies just keep growing, the article states. ZOLL is one of only 15 companies in the healthcare industry to make the list.
“While some of our business has softened with the economy since this data was collected, we are well-positioned for continued growth with the strength of our data management business and sales of the LifeVest® Wearable Defibrillator on track to increase 70 percent this fiscal year,” said Richard A. Packer, Chairman and Chief Executive Officer of ZOLL. “We are honored to receive this designation from Fortune and hope to be included in the coming years.”
Earlier this year, ZOLL received special recognition from Forbes.com as one of only 10 companies named to its list of America’s Most Trustworthy Companies for the three consecutive years it has published the list.
To compile the list for Fortune, three years of revenue, profit growth, and total revenue were tallied by Zacks Investment Research. For the first time, the list was opened to businesses around the world that trade on a U.S. exchange.
To qualify, a company—domestic or foreign—must be trading on a major U.S. stock exchange; file quarterly reports to the SEC; have a minimum market capitalization of $250 million on June 30, 2009; have a stock price of at least $5 on June 30, 2009; have been trading continuously since June 30, 2006; have revenue and net income for the four quarters ended on or before April 30, 2009 of at least $50 million and $10 million, respectively; and have posted a compound annual growth in revenue and earnings per share of at least 20% annually over the three years ended April 30, 2009.
The data from Zacks Investment Research was verified by Fortune using data provided by SunGard Fame, Standard & Poor’s Compustat, Hoover’s, Thomson Financial, and 10K Wizard. The full list can be viewed at http://money.cnn.com/magazines/fortune/fortunefastestgrowing/2009/full_list/.
ZOLL’s innovative resuscitation, therapeutic temperature management, and data management products have been instrumental in improving the quality of critical care and increasing patient survival rates.
